These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 526711)

  • 1. Species variation in the taurine conjugation of clofibric acid [proceedings].
    Caldwell J; Emudianughe TS; Smith RL
    Br J Pharmacol; 1979 Jul; 66(3):421P-422P. PubMed ID: 526711
    [No Abstract]   [Full Text] [Related]  

  • 2. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.
    Emudianughe TS; Caldwell J; Sinclair KA; Smith RL
    Drug Metab Dispos; 1983; 11(2):97-102. PubMed ID: 6133730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle.
    Meffin PJ; Zilm DM; Veenendaal JR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):732-8. PubMed ID: 6655566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A renal mechanism for the clofibric acid-probenecid interaction.
    Meffin PJ; Zilm DM; Veenendaal JR
    J Pharmacol Exp Ther; 1983 Dec; 227(3):739-42. PubMed ID: 6655567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs.
    Cayen MN; Ferdinandi ES; Greselin E; Robinson WT; Dvornik D
    J Pharmacol Exp Ther; 1977 Jan; 200(1):33-43. PubMed ID: 833760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utilization of exogenous taurine for the conjugation of xenobiotic acids in the ferret.
    Emudianughe TS; Caldwell J; Smith RL
    Xenobiotica; 1983 Mar; 13(3):133-8. PubMed ID: 6613158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of plafibride on erythrocyte deformability.
    Vilageliu J; Freixes J; Bruseghini L
    Arzneimittelforschung; 1983; 33(3):401-4. PubMed ID: 6683514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle.
    Rowe BJ; Meffin PJ
    J Pharmacol Exp Ther; 1984 Jul; 230(1):237-41. PubMed ID: 6747828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic].
    Lücker PW; Wetzelsberger K; Erking W; Donike M
    Arzneimittelforschung; 1980; 30(11b):2045-53. PubMed ID: 7194058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs.
    Zapatero J; Sanfeliu C; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1819-30. PubMed ID: 7198459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "The influence of conformational factors on the metabolic conjugation of aryloxyacetates"--a comment.
    Kennard CH; Smith G
    J Pharm Pharmacol; 1988 May; 40(5):380. PubMed ID: 2899641
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacology and mechanism of action of etofibrate].
    Schatton W
    Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic approach of plafibride in rat.
    Zapatero D; Vilageliu J; Torres A; Ribalta JM; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1800-4. PubMed ID: 7198457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicological studies of plafibride. Part 3: Study of teratogenic activity in rats and rabbits.
    Sanfeliu C; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1831-4. PubMed ID: 7198460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs.
    Garrett ER; Altmayer P
    J Pharm Sci; 1985 Mar; 74(3):295-9. PubMed ID: 4009437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological activities and side effects of plafibride.
    Gras J; Basi N; Zapatero J; Bermejo P; Gimenez F; Beascoa E; Llenas J; Bargalló MA; Giráldez A; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1808-16. PubMed ID: 6976173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicological studies of plafibride. Part 1: Acute toxicity and its determination after several administrations of plafibride.
    Zapatero J; Sanfeliu C; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1816-9. PubMed ID: 7198458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypolipemic effect of amino acid derivatives of clofibric acid].
    Wójcicki J; Samochowiec L; Gawrońska-Szklarz B; Kwapiszewski W; Borkowski L
    Acta Pol Pharm; 1985; 42(3):305-8. PubMed ID: 4096253
    [No Abstract]   [Full Text] [Related]  

  • 19. The analysis of [14C]clofibric acid glucuronide and [14C]clofibric acid in plasma and urine using high-performance liquid chromatography.
    Meffin PJ; Zilm DM
    J Chromatogr; 1983 Nov; 278(1):101-8. PubMed ID: 6662867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet antiaggregant activity of plafibride ex vivo in rat, dog and rabbit.
    Bruseghini L; Vilageliu J; Freixes J
    Arzneimittelforschung; 1981; 31(10a):1790-5. PubMed ID: 6797443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.